Nuvectis Pharma Inc. (NVCT): Price and Financial Metrics


Nuvectis Pharma Inc. (NVCT): $7.59

0.24 (+3.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NVCT Stock Price Chart Interactive Chart >

Price chart for NVCT

NVCT Price/Volume Stats

Current price $7.59 52-week high $20.92
Prev. close $7.35 52-week low $3.08
Day low $7.16 Volume 179,700
Day high $8.12 Avg. volume 463,039
50-day MA $7.12 Dividend yield N/A
200-day MA $9.42 Market Cap 111.13M

Nuvectis Pharma Inc. (NVCT) Company Bio


Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. It focuses on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its product pipeline includes NXP800 and NXP900. The company was founded by Ron Bentsur, Enrique Poradosu and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.


NVCT Latest News Stream


Event/Time News Detail
Loading, please wait...

NVCT Latest Social Stream


Loading social stream, please wait...

View Full NVCT Social Stream

Latest NVCT News From Around the Web

Below are the latest news stories about NUVECTIS PHARMA INC that investors may wish to consider to help them evaluate NVCT as an investment opportunity.

Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights

The dose escalation portion of the Phase 1 clinical trial of NXP800 is ongoing, and the Phase 1b dose expansion portion is expected to begin in Q1 2023 Investigational New Drug Application(“IND”)-enabling studies for NXP900 are ongoing, submission of IND or equivalent expected in Q1 2023Positive preclinical data for NXP800 in an ARID1a-mutated gastric cancer modelNXP800 poster presented at the 2022 ENA Conference on the validation of biomarkers supporting the clinical development of NXP800 NXP90

Yahoo | November 8, 2022

Nuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

FORT LEE, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the publication of abstracts for two posters that will be presented at the upcoming 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (“2022 ENA”), taking place from October 26t

Yahoo | October 18, 2022

Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders seem bullish, own 58% and have been buying more recently

To get a sense of who is truly in control of Nuvectis Pharma, Inc. ( NASDAQ:NVCT ), it is important to understand the...

Yahoo | October 17, 2022

Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference

FORT LEE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the Company’s management team will participate at the Roth Inaugural Healthcare Opportunities Conference. EventRoth Inaugural Healthcare Opportunities ConferenceDateOctober 6, 2022Time8:15 a.m. ETLocationNew York About

Yahoo | October 3, 2022

Nuvectis Pharma Announces Formation of a Scientific Advisory Board

FORT LEE, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the formation of a Scientific Advisory Board (“SAB”) comprised of world-renowned experts in translational science and clinical research that will help guide the Company’s research and development strategy. “As the evidence suppo

Yahoo | September 28, 2022

Read More 'NVCT' Stories Here

NVCT Price Returns

1-mo 8.43%
3-mo -8.44%
6-mo -37.53%
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6302 seconds.